Literature DB >> 23518465

Oxford classification of immunoglobulin A nephropathy: an update.

Ian S D Roberts1.   

Abstract

PURPOSE OF REVIEW: This review summarizes the recommendations for reporting immunoglobulin A (IgA) nephropathy biopsies and their evidence base, discusses the limitations of the Oxford Classification study and presents the findings of recent validation studies. RECENT
FINDINGS: The Oxford Classification identified four histological lesions as independent prognostic factors: mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S) and tubular atrophy/interstitial fibrosis (T). The MEST criteria predicted outcome in some, but not all, of 13 recent validation studies. M is of independent prognostic value in four out of 13 studies, S in four out of 13 and T in 10 out of 13. Apparently contradictory findings reflect differences in patient selection criteria, treatment and outcome measures. The Oxford Classification study provided indirect evidence that endocapillary hypercellularity is responsive to immunosuppressive therapy. This is confirmed in two validation studies. One study, which included patients with rapidly progressive disease, found glomerular crescents to be a significant prognostic marker. Immunohistological findings correlate with proliferative glomerular lesions but are not of independent prognostic value.
SUMMARY: The Oxford Classification is applicable to patients who were excluded from the original cohort, including those with rapidly progressive disease, and the prognostic value of proliferative glomerular lesions is influenced by immunosuppressive therapy. The Oxford schema will be reviewed in the light of recent findings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23518465     DOI: 10.1097/MNH.0b013e32835fe65c

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  17 in total

1.  Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.

Authors:  Aron Chakera; Clare MacEwen; Shubha S Bellur; La-Or Chompuk; Daniel Lunn; Ian S D Roberts
Journal:  J Nephrol       Date:  2015-08-30       Impact factor: 3.902

2.  Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.

Authors:  Xia-Hong Shen; Shao-Shan Liang; Hui-Mei Chen; Wei-Bo Le; Song Jiang; Cai-Hong Zeng; Min-Lin Zhou; Hai-Tao Zhang; Zhi-Hong Liu
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

3.  Mesangial C4d Deposits in Early IgA Nephropathy.

Authors:  Alfons Segarra; Katheryne Romero; Irene Agraz; Natalia Ramos; Alvaro Madrid; Clara Carnicer; Elias Jatem; Ramón Vilalta; Luis Enrique Lara; Elena Ostos; Naiara Valtierra; Juliana Jaramillo; Karla V Arredondo; Gema Ariceta; Cristina Martinez
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-16       Impact factor: 8.237

Review 4.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

Review 5.  Novel biomarkers in glomerular disease.

Authors:  Yasar Caliskan; Krzysztof Kiryluk
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

6.  Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; T Kahn; J Fahnert
Journal:  Clin Exp Immunol       Date:  2015-11-26       Impact factor: 4.330

Review 7.  Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients.

Authors:  Rosanna Coppo
Journal:  J Nephrol       Date:  2016-11-04       Impact factor: 3.902

8.  Oxidative stress and macrophage infiltration in IgA nephropathy.

Authors:  Yasar Caliskan; Erol Demir; Ecem Karatay; Yasemin Ozluk; Safak Mirioglu; Ahmet Burak Dirim; Ayse Serra Artan; Sebahat Usta Akgul; Ozgur Akin Oto; Fatma Savran Oguz; Aydin Turkmen; Krista L Lentine; Halil Yazici
Journal:  J Nephrol       Date:  2021-11-16       Impact factor: 3.902

Review 9.  IgA Nephropathy: An Interesting Autoimmune Kidney Disease.

Authors:  Arun Rajasekaran; Bruce A Julian; Dana V Rizk
Journal:  Am J Med Sci       Date:  2020-10-08       Impact factor: 2.378

10.  The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy.

Authors:  Jeffrey B Hodgin; Celine C Berthier; Rohan John; Elisabeth Grone; Stefan Porubsky; Hermann-Josef Gröne; Andrew M Herzenberg; James W Scholey; Michelle Hladunewich; Daniel C Cattran; Matthias Kretzler; Heather N Reich
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.